Therapeutics News and Research

RSS

Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults with autism spectrum disorders.

21 Jun 2011

Respira reports results of DPI drug engine clinical study against COPD, asthma

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.

21 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

Benitec’s pain program validated by independent study

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

20 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011

Patients still being enrolled in clinical trial for new peripheral vascular disease treatment

The first three patients to undergo an investigational surgical procedure for peripheral vascular disease that involves the patient's own stem cells continue to do well, reports the University of Louisville surgeon who is the principal investigator.

18 Jun 2011

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

17 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

Snack-based diet can increase risk of obesity

A high-fat diet can be bad for your health. However, a snack-based "cafeteria"-style diet of highly palatable, energy-dense foods is even worse, according to new research.

17 Jun 2011

CTI announces positive results from Phase I-II pixantrone combination study against INHL

Cell Therapeutics, Inc. announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Allos Therapeutics, Inc. today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Conference to discuss new diagnostic and treatment options for cognitive impairments in MS

On June 21-23, 2011, the New York Academy of Sciences will bring together physicians, neurologists, clinical neuropsychologists, cellular and molecular biologists and patient advocates to discuss current challenges and potential solutions for improving diagnosis, treatment and management of the cognitive symptoms of MS.

15 Jun 2011

Cardinal Health renews pharmaceutical distribution agreement with Prime Therapeutics

Cardinal Health today announced that it has signed a renewed, three-year agreement with Prime Therapeutics, one of the nation's leading pharmacy benefit managers, to continue to serve as its primary pharmaceutical supply chain partner for its mail-service pharmacy, PrimeMail®.

15 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

University of British Columbia researchers - using an innovative, atom-by-atom substitution method - have uncovered the mechanism by which a particular class of drugs controls irregular heartbeats.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

Therapeutics News and Research

Seaside Therapeutics commences STX209 Phase 2b study in autism spectrum disorders

Respira reports results of DPI drug engine clinical study against COPD, asthma

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Benitec’s pain program validated by independent study

Genomic study identifies MCU that regulates calcium transport into mitochondria

Patients still being enrolled in clinical trial for new peripheral vascular disease treatment

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Innovative adult stem cell approach could help eliminate obesity

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Snack-based diet can increase risk of obesity

CTI announces positive results from Phase I-II pixantrone combination study against INHL

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Conference to discuss new diagnostic and treatment options for cognitive impairments in MS

Cardinal Health renews pharmaceutical distribution agreement with Prime Therapeutics

Galectin strengthens cancer drug patent portfolio in Europe

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News